Endometrial Cancer – Adding Herceptin to the Standard Protocol Prolongs Patients’ Lives
Background – Endometrial cancer and this trial Uterine-serous-carcinoma, USC, is an aggressive variant of endometrial cancer. This phase II trial evaluated Carboplatin+Taxol versus Herceptin +Carboplatin+Taxol
Trial – Berzosertib can neutralize the cancer’s ability to repair itself
Berzosertib – Trial Rational Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA
Gastric Cancer – Enhertu in HER2-Positive patients
Background Enhertu is a conjugate of an antibody which is anti-HER2 and chemo drug. Enhertu may have efficacy in patients with HER2-positive advanced gastric cancer.
Breast Cancer – Pyrotinib/Xeloda beats Tykerb/Xeloda
Background Pyrotinib is an innovative cancer drug targeting EGFR, HER2, and HER4 which are components expressed on cell surface. Pyrotinib plus Xeloda has shown meaningful
Colon cancer – recently approved drug for breast cancer, Enhertu, show promise
Colon cancer treated with Enhertu Enhertu is an antibody-drug conjugate composed of a chemotherapy bound to an anti-HER2 antibody. Recently, in December 2019, Enhertu received
Triple Negative Breast Cancer: Halaven plus Keytruda
About the two study drugs in Triple Negative Breast Cancer Both study drugs are FDA approved. Halaven is approved for advanced breast cancer and Keytruda
Glioblastoma: Epilepsy drug plus standard treatment
Background about Glioblastoma Glioblastoma, GBM, is an aggressive and the most frequent malignant brain tumor primary brain tumor with poor prognosis. At diagnosis, the standard
Lung cancer and thyroid – First RET+ drug, Retevmo
The FDA has approved Retevmo capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This is the first therapy
Kidney Cancer – Opdivo plus Cabometyx prolong life
Background Patients with advanced or metastatic kidney cancer are a population that despite recent advances remains in need of additional therapeutic options that extend survival.
Compassionate Drugs – What are they?
“Compassionate drugs“, also called “named patient drugs” or “early access drugs”. Compassionate drugs can be one of three cases: Compassionate drugs (1) – Can be
Chondrosarcoma – Ivosidenib works in Chondrosarcoma
Chondrosarcoma and IDH1 – Background For locally advanced and/or metastatic Chondrosarcoma, no known effective therapy exists. The standard protocols are not effective. Mutations in the
GBM that disappeared from Monica’s MRI from 4.3.20
Monica (not her real name), a 43-year-old Cyprus resident, was diagnosed with GBM brain cancer, Glioblastoma, two years ago. One year ago Monica’s husband contacted
